Adenosine Receptor A3 (ADORA3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) – Pipeline Review, H2 2016’, provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Adenosine Receptor A3 (ADORA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Can-Fite BioPharma Ltd.

Huons Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Adenosine Receptor A3 (ADORA3) Overview 6

Therapeutics Development 7

Adenosine Receptor A3 (ADORA3) - Products under Development by Stage of Development 7

Adenosine Receptor A3 (ADORA3) - Products under Development by Therapy Area 8

Adenosine Receptor A3 (ADORA3) - Products under Development by Indication 9

Adenosine Receptor A3 (ADORA3) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Adenosine Receptor A3 (ADORA3) - Products under Development by Companies 14

Adenosine Receptor A3 (ADORA3) - Products under Development by Universities/Institutes 16

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development 24

Can-Fite BioPharma Ltd. 24

Huons Co., Ltd. 25

Adenosine Receptor A3 (ADORA3) - Drug Profiles 26

ACN-1052 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CF-102 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CF-602 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

HU-010 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

LJ-1888 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

PBF-1650 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PBF-677 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

piclidenoson - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Adenosine Receptor A3 (ADORA3) - Dormant Projects 46

Adenosine Receptor A3 (ADORA3) - Discontinued Products 48

Adenosine Receptor A3 (ADORA3) - Featured News & Press Releases 49

Aug 08, 2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology 49

Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD 49

Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data 50

Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects 50

Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) 51

Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis 52

May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting 52

Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose 53

Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis 53

Jan 19, 2016: U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602 54

Jan 11, 2016: Can-Fite Announces Update on CF101 55

Jan 11, 2016: Can-Fite Announces Update on CF102 55

Jan 11, 2016: Can-Fite Announces Update on CF602 56

Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis 56

Dec 17, 2015: Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Comparative Analysis by Unknown Stage Development, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Can-Fite BioPharma Ltd., H2 2016 24

Pipeline by Huons Co., Ltd., H2 2016 25

Dormant Projects, H2 2016 46

Dormant Projects (Contd..1), H2 2016 47

Discontinued Products, H2 2016 48

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports